BGOG-cx20/Trofuse-020

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer 

Open
Trial drug
MK-2870
Prior lines
1
Histology
Squamous, Adeno
Phase
III

Treatment

This study consists of 2 different treatment options:

  • MK-2870
  • Physician's choice treatment

You will be randomly allocated to one of both treatment groups.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.